A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTIN™), in Patients With Advanced Solid Tumours
Phase 1
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Solid Tumors
Both
Solid Tumors
Trial Information
A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTIN™), in Patients With Advanced Solid Tumours
Inclusion Criteria:
- Written informed consent
- Prostate cancer), which is refractory to standard therapies or for which no standard
therapy exists.
- Estimated life expectancy of at least 8 weeks
- WHO performance status (PS) 0-2.
Exclusion Criteria:
- Unstable brain/meningeal metastases
- Biochemistry/haematology results outside of required ranges
- History of significant GI impairment
- Inadequate bone marrow reserve
Type of Study:
Interventional
Study Design:
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To assess the steady-state PK parameters of cediranib in the presence and absence of rifampicin
Outcome Time Frame:
PK assessments to be taken until Day 28. Days 7 and 14 PK parameters used to assess the primary variables.
Safety Issue:
No
Principal Investigator
Jane Robertson
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca, Alderley Park
Authority:
Canada: Health Canada
Study ID:
D8480C00029
NCT ID:
NCT00750841
Start Date:
September 2008
Completion Date:
June 2013
Related Keywords:
- Solid Tumors
- advanced cancer
- metastatic
- rifampicin
- pharmacokinetics
- Phase I
- Advanced solid tumours
- Neoplasms
Name | Location |
|---|
